Calendar | For Your Patients | PHA Main Site | Contact Us | About Us | Not a registered user? Sign up here.

PHA Partners & Events

Innovations in Heart Failure and Pulmonary Hypertension

October 5, 2018

Omni Willliam Penn Hotel
530 William Penn Place
Pittsburgh, Pennsylvania 15219

Both heart failure and pulmonary hypertension remain a major burden on society with a very high morbidity and mortality. Heart failure is the leading cause of cardiovascular death and the number one cause of hospitalization in the United States. Pulmonary hypertension often co-exists with heart failure and worsens morbidity and mortality. Heart failure is also a leading cause of cardiogenic shock which carries with a greater than 80% in hospital mortality. Several large clinical trials conducted over the past two decades have shown that pharmacologic interventions, surgery, and device- therapy can dramatically reduce the morbidity and mortality associated with both heart failure and pulmonary hypertension.

Based on evidence, new clinical practice guidelines have been developed for medical and surgical management of these patients. Despite these evidence-based guidelines, it has been shown that providers do not consistently follow recommendations in clinical practice. Unfortunately, this often results in patients being referred late in the disease for advanced therapies, leading to their unsuitability for such therapies.

More Information:

Contact Information: Bernice Sulkowski
Coordinator, Continuing Medical Education